S. Grootenboer‐Mignot

发表

Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients

T. Gille, C. Prost-Squarcioni, S. Grootenboer-Mignot, 2022, Frontiers in Immunology.

Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort

M. Dougados, P. Dieudé, G. Serre, 2012, Annals of the rheumatic diseases.

Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis.

F. Tubach, L. Michel, A. Mailleux, 2011, American journal of respiratory and critical care medicine.

Autoantibodies are associated with disease progression in idiopathic pulmonary fibrosis

S. Chevret, V. Cottin, V. Besnard, 2023, European Respiratory Journal.

Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa

Antoine Martin, C. Prost-Squarcioni, E. Maubec, 2019, Front. Med..

Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases.

Z. Amoura, B. Bader-Meunier, P. Rémy, 2017, Seminars in arthritis and rheumatism.

Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients

N. Lièvre, S. Doan, P. Musette, 2022, Frontiers in Immunology.

Paraneoplastic pemphigus uncovers distinct clinical and biological phenotypes of western unicentric Castleman disease

É. Oksenhendler, P. Mordant, V. Meignin, 2023, British journal of haematology.

Neonatal and self‐healing linear immunoglobulin A dermatosis

C. Bodemer, S. Hadj-Rabia, O. Boccara, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus

P. Dieudé, O. Meyer, S. Chollet-Martin, 2009, Arthritis research & therapy.

Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome.

O. Meyer, S. Chollet-Martin, G. Hayem, 2008, Rheumatology.

A second locus mapping to 2q35–36 for familial pseudohyperkalaemia

P. Gasparini, M. Carella, A. Iolascon, 2004, European Journal of Human Genetics.

Erythema multiforme associated with anti‐plakin antibodies: a multicentric retrospective case series

P. Wolkenstein, S. Chollet-Martin, V. Descamps, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Pemphigus in Elderly Adults: Clinical Presentation, Treatment, and Prognosis

P. Wolkenstein, O. Chosidow, E. Mahé, 2012, Journal of the American Geriatrics Society.

Epidermolysis bullosa acquisita‐like eruption with anticollagen VII autoantibodies induced by d‐penicillamine in Wilson disease

P. Wolkenstein, O. Chosidow, E. Laffitte, 2014, The British journal of dermatology.

Rituximab, a new treatment for difficult‐to‐treat chronic erythema multiforme major? Five cases

P. Wolkenstein, O. Chosidow, N. Ortonne, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults

P. Wolkenstein, E. Sbidian, O. Chosidow, 2017, The British journal of dermatology.

Sub‐lethal hydrops as a manifestation of dehydrated hereditary stomatocytosis in two consecutive pregnancies

I. Laurendeau, J. Delaunay, T. Cynober, 2003, Prenatal diagnosis.

Comparison of 3 type VII collagen (C7) assays for serologic diagnosis of epidermolysis bullosa acquisita (EBA).

A. Hovnanian, M. Titeux, J. Bonnefoy, 2016, Journal of the American Academy of Dermatology.

Anti-C 1 q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus

P. Dieudé, O. Meyer, S. Chollet-Martin, 2015 .

Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.

P. Dieudé, O. Meyer, S. Chollet-Martin, 2009, Joint, bone, spine : revue du rhumatisme.

Perip7lakin is a target for autoimmunity in asthma

B. Crestani, C. Estellat, S. Chollet-Martin, 2016, Respiratory Research.

Place of human amniotic membrane immunoblotting in the diagnosis of autoimmune bullous dermatoses

S. Chollet-Martin, B. Crickx, V. Descamps, 2009, The British journal of dermatology.

Non‐coeliac gluten sensitivity: an underdiagnosed condition in dermatology?

V. Descamps, L. Deschamps, J. El Khalifa, 2021, Journal of the European Academy of Dermatology and Venereology.

Levels of anticardiolipin and anti-β2-glycoprotein I antibodies in healthy newborn cord sera

L. Carbillon, S. Chollet-Martin, O. Fain, 2008, Thrombosis and Haemostasis.

Drug‐induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases

M. Beylot-Barry, G. Jeudy, V. Descamps, 2019, British journal of clinical pharmacology.

Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis.

F. Tubach, L. Michel, A. Mailleux, 2011, American journal of respiratory and critical care medicine.

Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.

P. Dieudé, O. Meyer, S. Chollet-Martin, 2009, Joint, bone, spine : revue du rhumatisme.

IgA and IgG/IgA intercellular dermatosis: a clinicopathological case series of 15 patients

N. Dupin, N. Ortonne, P. Schoenlaub, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Lichen planus pemphigoides with predominant mucous membrane involvement: a series of 12 patients and a literature review

C. Prost-Squarcioni, M. Alexandre, I. Soued, 2024, Frontiers in Immunology.

Severe sequelae of erythema multiforme: three cases

P. Wolkenstein, O. Chosidow, É. Béquignon, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Second generation anti‐cyclic citrullinated peptide (anti‐CCP2) antibodies can replace other anti‐filaggrin antibodies and improve rheumatoid arthritis diagnosis

O. Meyer, S. Chollet-Martin, S. Grootenboer-Mignot, 2004, Scandinavian journal of rheumatology.